Figure 3.Kaplan-Meier curve for time to tumor progression for gliomas with different IDH status. The PFS of patients with IDH mutation was longer than that of IDH-wild type patients.
Figure 3 — The prognosis of gliomas with different molecular subtypes in the era of intensity-modulated radiation therapy (IMRT) | Aging
